Exhibit 99.1


[ABAXIS LOGO]

Contact:     Clint Severson                     RCG Capital Markets Group
             Chief Executive Officer            Retail: Joe Dorame
             ABAXIS, Inc.                       Institutional/Analysts: Joe Diaz
             510-675-6501                       Media: Jeff Stanlis
                                                480-675-0400

                                                           FOR IMMEDIATE RELEASE


                  ABAXIS TO COMPLY WITH PRELIMINARY INJUNCTION
                       WHILE EVALUATING ITS LEGAL OPTIONS




Union City, California - September 4, 2002 -- ABAXIS, Inc. (NASDAQ: ABAX)
announced that on September 3, 2002, the United States District Court of Maine
issued a preliminary injunction in favor of IDEXX Laboratories, Inc. under which
Abaxis cannot, pending the resolution of patent litigation by IDEXX against
Abaxis, make, use, sell, offer to sell or import the VetScan Canine Heartworm
Antigen Test manufactured by S.A. Scientific, Inc. of San Antonio, Texas and
sold by Abaxis. Abaxis disagrees with the Court's opinion and is evaluating its
legal options, including an appeal of the order to the Federal Circuit Court of
Appeals.

The VetScan canine heartworm test was introduced in December 2001 and
constitutes approximately 3% of total Abaxis sales since that date. The granting
of the preliminary injunction does not affect the sale and support of Abaxis'
in-clinic veterinary chemistry and hematology analysis products, which form the
core of Abaxis' VetScan line.

"Although we disagree with the decision regarding the canine heartworm test, we
of course plan to comply fully with the order," stated Clint Severson, CEO and
Chairman of the Board.

ABAXIS develops, manufactures and markets portable blood analysis systems for
use in any patient-care setting to provide clinicians with rapid blood
constituent measurements. The system consists of a compact, 6.9 kilogram,
portable analyzer and a series of 8-cm diameter single-use plastic disks, called
reagent discs, which contain all the reagents necessary to perform a fixed menu
of tests. The system can be operated with minimal training and perform multiple
tests on whole blood, serum, or plasma. The system provides test results in less
than 14 minutes with the precision and accuracy equivalent to a clinical
laboratory.

This press release includes statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. ABAXIS claims the protection of the safe-harbor for forward-looking
statements contained in the Reform Act. Specific forward-looking statements
contained in this press release include, but are not limited to, risks and
uncertainties that:

- -    Abaxis may be forced to pay Idexx monetary damages, be permanently enjoined
     from selling the canine heartworm product manufactured by S.A. Scientific,
     need to enter into a license agreement with Idexx pertaining to the
     patents, or a combination thereof;

- -    In the event that Abaxis is enjoined from selling the canine heartworm
     antigen test manufactured by S.A. Scientific, Abaxis may be unable to
     either develop an alternate canine heartworm product that does not infringe
     upon the Idexx patents or Idexx may offer Abaxis commercially unfeasible
     terms for licensing their patents; and

- -    Even if Abaxis is successful in defending against the Idexx action, the
     defense of such claims may be exorbitant and may divert Abaxis management's
     focus away from running Abaxis' business


Other risks and uncertainties related to Abaxis' business are detailed from time
to time in Abaxis' periodic reports filed with the United States Securities and
Exchange Commission. Forward-looking statements speak only as of the date the
statement was made. Abaxis does not undertake and specifically disclaims any
obligation to update any forward-looking statements.